Use of Alfentanil in Palliative Care

José António Ferraz Gonçalves, Filipa Sousa, Lucy Alves, Patrícia Liu, Sara Coelho, José António Ferraz Gonçalves, Filipa Sousa, Lucy Alves, Patrícia Liu, Sara Coelho

Abstract

Alfentanil is used for chronic pain relief in palliative care. However, there is a dearth of data on its use. For this reason, a decision was made to review the use of alfentanil in palliative care. Retrospective study was carried out in a palliative care service. The files of patients who received alfentanil as an intravenous or subcutaneous continuous infusion for pain relief, between January 2018 and April 2019. In total, 111 patients received alfentanil out of 113 admissions. Of them, 56 were male, and the median age was 70 years. The median number of days on alfentanil was 6 (range 1 to 129). The most frequent primary reasons for switching to alfentanil was uncontrolled pain in 52 (46%) patients and renal impairment in 24 (21%) patients. The median 24-h initial dose of alfentanil was 4 mg (1-20), and the median final 24-h dose of alfentanil was 5 mg (1-60), (p < 0.001). The initial 24-h median number of rescue doses was 2 (0-8), and the final median number of rescue doses was 1 (0 to 8), (p = 0.025). In 56 patients who were on alfentanil for at least 7 days, the dose decreased in 3 (5%), remained stable in 10 (18%) and increased in 43 (77%). The patient on alfentanil for 129 days maintained the same dose throughout that period. Alfentanil can be a useful second-line opioid. The induction of tolerance does not seem to be particularly rapid with alfentanil.

Keywords: alfentanil; pain relief; palliative care; renal impairment.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall survival.

References

    1. World Health Organization . Cancer Pain Relief. 2nd ed. World Health Organization; Geneva, Switzerland: 1996. [(accessed on 16 December 2020)]. Available online: .
    1. Treillet E., Laurent S., Hadjiat Y. Practical management of opioid rotation and equianalgesia. J. Pain Res. 2018;11:2587–2601. doi: 10.2147/JPR.S170269.
    1. Reitz J.A. Alfentanil in Anesthesia and Analgesia. Drug Intell. Clin. Pharm. 1986;20:335–341. doi: 10.1177/106002808602000501.
    1. Miner J.R., Driver B.E., Moore J.C., Faegerstrom E., Klein L., Prekker M., Cole J.B. Randomized clinical trial of propofol versus alfentanil for moderate procedural sedation in the emergency department. Am. J. Emerg. Med. 2017;35:1451–1456. doi: 10.1016/j.ajem.2017.04.041.
    1. Urch E.C., Carr S., Minton O. A retrospective review of the use of alfentanil in a hospital palliative care setting. Palliat. Med. 2004;18:516–519. doi: 10.1191/0269216304pm910oa.
    1. Janssen Rapifen® Injection Product Information. [(accessed on 17 December 2019)]; Available online: .
    1. Launay-Vacher V., Oudard S., Janus N., Gligorov J., Pourrat X., Rixe O., Morere J.-F., Beuzeboc P., Deray G., On behalf of the Renal Insufficiency and Cancer Medications (IRMA) Study Group Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management. Cancer. 2007;110:1376–1384. doi: 10.1002/cncr.22904.
    1. Kirkham S., Pugh R. Opioid analgesia in uraemic patients. Lancet. 1995;345:1185. doi: 10.1016/S0140-6736(95)91019-0.
    1. King S.J., Forbes K., Hanks G.W., Ferro C.J., Chambers E.J. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project. Palliat. Med. 2011;25:525–552. doi: 10.1177/0269216311406313.
    1. Cran A., Dorman S., Kirkham S. Opioid rotation to alfentanil: Comparative evaluation of conversion ratios. BMJ Support. Palliat. Care. 2017;7:265–266. doi: 10.1136/bmjspcare-2017-001349.
    1. Ohno Y., Hisaka A., Suzuki H. General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs. Clin. Pharmacokinet. 2007;46:681–696. doi: 10.2165/00003088-200746080-00005.
    1. Kissin I., Bright C.A., Bradley E.L. Acute tolerance to continuously infused alfentanil: The role of Cholecystokinin and N-Methyl-D-Aspartate-Nitric Oxide Systems. Anesth. Analg. 2000;91:110–116.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe